IASO Bio inks partnership with Instituto Butantan to develop innovative therapy for haematological cancer: Shanghai, Nanjing Monday, April 13, 2026, 12:00 Hrs [IST] IASO Biotechno ...
MetaVia begins patient dosing in Part 3 of phase 1 study of DA-1726, a GLP-1 and glucagon dual agonist to treat obesity: Cambridge, Massachusetts Monday, April 13, 2026, 11:00 Hrs ...
UK MHRA approves Sobi’s olezarsen for the treatment of familial chylomicronemia syndrome: United Kingdom Monday, April 13, 2026, 10:00 Hrs [IST] The Medicines and Healthcare pro ...
IPA CPD announces Regional Convention 2026 on May 17 in Goa to advance professionalism in pharmacy practice: Our Bureau, Chennai Monday, April 13, 2026, 09:00 Hrs [IST] The Commun ...
DCC recommends shifting of four drugs from Schedule H to H1 to bring them under tighter regulation: Gireesh Babu, New Delhi Monday, April 13, 2026, 08:00 Hrs [IST] The Drugs Consu ...
EFDA collaborates with Indian Pharma to meet Ethiopia’s regulatory requirements for faster drug approvals: Shardul Nautiyal, Mumbai Monday, April 13, 2026, 08:00 Hrs [IST] The E ...
DCC forms sub-committee to look into feasibility of public disclosure of RBI details: Gireesh Babu, New Delhi Monday, April 13, 2026, 08:00 Hrs [IST] The Drugs Consultative Commit ...
RDCA pushes for 'essential emergency service' status for pharma logistics: Peethaambaran Kunnathoor, Chennai Monday, April 13, 2026, 08:00 Hrs [IST] The Retail Distribution Chemis ...
Alexion to deliver 20 presentations across gMG, NF1 plexiform neurofibromas and neuromyelitis optica spectrum disorder at AAN meeting: Cambridge, UK Saturday, April 11, 2026, 18:0 ...
Sparian Biosciences begins phase 1 clinical trial of SBS-147; a next generation arylepoxamide receptor agonist to treat pain: New York Saturday, April 11, 2026, 15:00 Hrs [IST] Sp ...
Max Institute of Cancer Care, Vaishali, redefines cancer care through advanced technology; Brings top oncologists together at ONCO-CON 2026: Our Bureau, Mumbai Saturday, April 11, ...
Boehringer Ingelheim to evaluate combination of DLL3-targeting T-cell engager plus PD-L1/VEGF-A bispecific antibody in small cell lung cancer: Ingelheim, Germany Saturday, April 1 ...